Alvotech

Alvotech announced that Celtic Lux Holdings S.a. r.l., a closely associated person, pledged a significant portion of its holdings. This included 88,940,619 shares and 7,007,321 depository receipts on shares. The transactions occurred on June 26, 2026, and were reported to the Luxembourg Commission de Surveillance du Secteur Financier (CSSF).

Alvotech announced it has secured an additional $75 million term loan facility, led by GoldenTree Asset Management, maturing on December 31, 2027. This financing, bearing a 12.50% interest rate, strengthens the company's financial position following a recent $165 million equity raise. Including the equity financing and the undrawn loan facility, Alvotech has secured access to $240 million in new capital to support its growth strategy, including advancing its biosimilar pipeline and expanding global commercial operations.

Alvotech announced an amendment to its credit agreement, securing an additional $75 million term loan facility led by GoldenTree Asset Management. This financing, combined with a recent $165 million equity capital raise, provides the company with access to $240 million in new capital. The funds will be used to strengthen Alvotech's financial position, advance its biosimilar pipeline, support product launches, and expand global commercial operations.

Alvotech announced an amendment to its credit agreement, securing an additional $75 million term loan facility from GoldenTree Asset Management and other lenders. This financing, which matures on December 31, 2027, and bears a 12.50% interest rate, follows a recent $165 million equity raise. The combined capital of $240 million will strengthen the company's financial position and support its growth strategy, including advancing its biosimilar pipeline and expanding global commercial operations.

Alvotech announced the closing of its underwritten public offering of 26,066,667 ordinary shares at $3.75 per share, generating approximately $98 million in gross proceeds. Concurrently, the company entered into subscription agreements for a private placement of 17,826,666 ordinary shares at the same price, expected to yield about $67 million. The total gross proceeds from both offerings are anticipated to be approximately $165 million, which Alvotech plans to use for continued development of its biosimilar assets, working capital, and general corporate purposes.

Alvotech announced the closing of its underwritten public offering, raising approximately $98 million in gross proceeds from the sale of 26,066,667 ordinary shares at $3.75 each, including the full exercise of the underwriters' option. Concurrently, the company entered into subscription agreements for a private placement of 17,826,666 ordinary shares at the same price, expected to generate about $67 million. The combined gross proceeds from both transactions are anticipated to be approximately $165 million, which Alvotech plans to use for continued development of its biosimilar assets, working capital, and general corporate purposes.

Alvotech has announced the commencement of an underwritten public offering of its ordinary shares, with an option for underwriters to purchase additional shares. The company anticipates raising approximately $125 million through this offering and a concurrent private placement. The net proceeds are earmarked for the continued development of its biosimilar assets, working capital, and general corporate purposes. BofA Securities, Jefferies, and Evercore ISI are serving as joint book-running managers for the offering.

Alvotech announced the pricing of its underwritten public offering of 22,666,667 ordinary shares at $3.75 per share, expecting gross proceeds of approximately $85 million. Concurrently, the company entered into subscription agreements for a private placement of 17,826,666 ordinary shares at the same price, anticipating gross proceeds of about $67 million. The combined offerings are expected to generate approximately $152 million, or up to $165 million if underwriters fully exercise their option. Proceeds will fund biosimilar asset development, working capital, and general corporate purposes.

Alvotech announced the termination of its prospectus supplement related to the potential issuance of ordinary shares through an At-The-Market (ATM) offering. Effective June 15, 2026, the company will suspend its use of this supplement, meaning no further sales of securities will occur under the existing Sales Agreement until a new prospectus supplement or registration statement is filed. The underlying Sales Agreement with Jefferies LLC, however, remains active.

Alvotech announced the commencement of an underwritten public offering of its ordinary shares. Concurrently, the company expects to conduct a private placement with certain investors at the public offering price. Alvotech anticipates raising approximately $125 million in gross proceeds from both offerings. The funds are intended to support the continued development of its biosimilar assets, working capital, and general corporate purposes, including potential acquisitions and debt repayment.